Windtree Therapeutics, Inc.(WINT)Earnings, Financials & Key Ratios
WINT•NASDAQ
$0.02
$1078 mkt cap·Price updated May 6, 2026
AboutWindtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.Show more
- Revenue$0
- EBITDA-$25M-42.8%
- Net Income-$5M+73.0%
- EPS (Diluted)-104.35+97.8%
- ROE-81.98%+72.9%
- ROIC-144.67%-21.1%
- Debt/Equity0.18-96.3%
- Interest Coverage-106.46+69.6%
WINT Key Insights
Windtree Therapeutics, Inc. (WINT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
- ✓Trading at only 0.0x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
WINT Price & Volume
Windtree Therapeutics, Inc. (WINT) stock price & volume — 10-year historical chart
Loading chart...
WINT Growth Metrics
Windtree Therapeutics, Inc. (WINT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-320.85%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM99.09%
Return on Capital
10 Years-85.91%
5 Years-69.53%
3 Years-77.43%
Last Year-98.95%
WINT Peer Comparison
Windtree Therapeutics, Inc. (WINT) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CRVS | 1.15B | 15.45 | -29.15 | -23.29% | 0.02 | |||
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 AGIO | 1.6B | 26.98 | -3.79 | 48.03% | -6.4% | -34.11% | 0.05 | |
 PRTA | 601.85M | 11.18 | -2.47 | -92.84% | -25.21% | -73% | 0.05 | |
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 | |
 INSM | 29.14B | 137.09 | -21.35 | 66.73% | -264.83% | -125.2% | 0.06 | |
 MRK | 280.48B | 113.56 | 15.60 | 1.18% | 28.12% | 36.14% | 0.96 |
Compare WINT vs Peers
Windtree Therapeutics, Inc. (WINT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
WINT Income Statement
Windtree Therapeutics, Inc. (WINT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 2.04M | 1.49M | 1.79M | 198K | 0 | 0 | 0 | 0 | 0 | 90K |
| Revenue Growth % | 106.89% | -27.28% | 20.4% | -88.93% | -100% | - | - | - | - | - |
| Cost of Goods Sold | 255K | 17.38M | 10.56M | 12.69K | 638K | 869K | 1.06M | 82K | 84K | 34K |
| COGS % of Revenue | 12.49% | 1170.1% | 590.72% | 6.41% | - | - | - | - | - | - |
| Gross Profit | 1.79M▲ 0% | -15.89M▼ 989.3% | -8.77M▲ 44.8% | 185.31K▲ 102.1% | -638K▼ 444.3% | -869K▼ 36.2% | -1.06M▼ 22.1% | -82K▲ 92.3% | -84K▼ 2.4% | 11K▲ 0% |
| Gross Margin % | 87.51% | -1070.1% | -490.72% | 93.59% | - | - | - | - | - | 12.22% |
| Gross Profit Growth % | 2981.03% | -989.26% | 44.79% | 102.11% | -444.28% | -36.21% | -22.09% | 92.27% | -2.44% | - |
| Operating Expenses | 40.08M | 24.03M | 17.98M | 25.09M | 30.32M | 31.39M | 20.43M | 17.46M | 24.93M | 33.5M |
| OpEx % of Revenue | 1962.68% | 1618.38% | 1005.76% | 12672.22% | - | - | - | - | - | - |
| Selling, General & Admin | 8.37M | 6.66M | 7.42M | 12.4M | 14.94M | 14.47M | 10.79M | 9.2M | 8.74M | 7.71M |
| SG&A % of Revenue | 410.04% | 448.28% | 415.04% | 6264.65% | - | - | - | - | - | - |
| Research & Development | 31.7M | 17.38M | 10.56M | 12.69M | 15.37M | 17.79M | 11.1M | 8.26M | 16.28M | 8.54M |
| R&D % of Revenue | 1552.64% | 1170.1% | 590.72% | 6407.58% | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 129K | 401K | 0 | 0 | -869K | -1.46M | 0 | -84K | 2M |
| Operating Income | -38.04M▲ 0% | -22.55M▲ 40.7% | -16.2M▲ 28.2% | -24.89M▼ 53.7% | -30.32M▼ 21.8% | -77.28M▼ 154.9% | -41.33M▲ 46.5% | -17.54M▲ 57.6% | -25.02M▼ 42.6% | -13.62M▲ 0% |
| Operating Margin % | -1862.68% | -1518.38% | -905.76% | -12572.22% | - | - | - | - | - | -15127.78% |
| Operating Income Growth % | 4.51% | 40.72% | 28.18% | -53.71% | -21.79% | -154.91% | 46.52% | 57.57% | -42.65% | - |
| EBITDA | -37.78M | -22.36M | -16.04M | -23.78M | -29.68M | -76.41M | -40.27M | -17.46M | -24.93M | -13.56M |
| EBITDA Margin % | -1850.2% | -1505.45% | -896.87% | -12010.61% | - | - | - | - | - | -15070% |
| EBITDA Growth % | 3.43% | 40.83% | 28.27% | -48.3% | -24.8% | -157.46% | 47.3% | 56.65% | -42.84% | 46.09% |
| D&A (Non-Cash Add-back) | 255K | 192K | 159K | 1.11M | 638K | 869K | 1.06M | 82K | 84K | 52K |
| EBIT | -36.97M | -16.58M | -19.12M | -26.98M | -32.44M | -77.51M | -40.52M | -20.24M | -1.56M | -11.83M |
| Net Interest Income | -2.5M | -1.85M | -1.39M | -342K | -3K | -23K | 56K | 275K | -165K | 53K |
| Interest Income | 18K | 12K | 15K | 153K | 122K | 91K | 109K | 325K | 70K | 971K |
| Interest Expense | 2.52M | 1.86M | 1.41M | 495K | 125K | 114K | 53K | 50K | 235K | -168K |
| Other Income/Expense | -1.45M | 4.1M | -4.34M | -2.58M | -2.25M | -45.36M | 758K | -2.75M | 23.23M | 1.63M |
| Pretax Income | -39.49M▲ 0% | -18.45M▲ 53.3% | -20.53M▼ 11.3% | -27.48M▼ 33.8% | -32.57M▼ 18.5% | -77.62M▼ 138.4% | -40.58M▲ 47.7% | -20.29M▲ 50.0% | -1.79M▲ 91.2% | -43.5M▲ 0% |
| Pretax Margin % | -1933.89% | -1242.15% | -1148.38% | -13876.26% | - | - | - | - | - | -48335.56% |
| Income Tax | 0 | 0 | 0 | 0 | -2.29M | -9.99M | -1.37M | 0 | 3.69M | 3.35M |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 7.02% | 12.87% | 3.37% | 0% | -206.02% | -7.71% |
| Net Income | -39.49M▲ 0% | -18.45M▲ 53.3% | -20.53M▼ 11.3% | -27.48M▼ 33.8% | -30.28M▼ 10.2% | -67.64M▼ 123.4% | -39.21M▲ 42.0% | -20.29M▲ 48.2% | -5.49M▲ 73.0% | -40.86M▲ 0% |
| Net Margin % | -1933.89% | -1242.15% | -1148.38% | -13876.26% | - | - | - | - | - | -45395.56% |
| Net Income Growth % | 28.42% | 53.29% | -11.31% | -33.81% | -10.21% | -123.37% | 42.03% | 48.25% | 72.96% | -320.85% |
| Net Income (Continuing) | -39.49M | -18.45M | -20.53M | -27.48M | -30.28M | -67.64M | -39.21M | -20.29M | -5.49M | -11.91M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -999999.00▲ 0% | -999999.00▲ 0.0% | -999999.00▲ 0.0% | -113138.00▲ 88.7% | -93616.00▲ 17.3% | -122924.00▼ 31.3% | -56011.00▲ 54.4% | -4711.54▲ 91.6% | -104.35▲ 97.8% | -1531.62▲ 0% |
| EPS Growth % | 40.06% | 74.57% | 67.96% | 89.17% | 17.26% | -31.31% | 54.43% | 91.59% | 97.79% | 99.09% |
| EPS (Basic) | -999999.00 | -999999.00 | -999999.00 | -113138.00 | -93616.00 | -122924.00 | -56011.00 | -4711.54 | -104.35 | - |
| Diluted Shares Outstanding | 3 | 8 | 33 | 243 | 348 | 550 | 700 | 4.31K | 52.58K | 26.68K |
| Basic Shares Outstanding | 3 | 8 | 33 | 243 | 348 | 550 | 700 | 4.31K | 52.58K | 26.68K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
WINT Balance Sheet
Windtree Therapeutics, Inc. (WINT) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 7.19M | 2.24M | 25.65M | 23.86M | 18.12M | 23.49M | 7.38M | 5.38M | 2.57M | 7.21M |
| Cash & Short-Term Investments | 5.59M | 1.81M | 25.15M | 22.58M | 16.93M | 22.35M | 6.17M | 4.32M | 1.78M | 204K |
| Cash Only | 5.59M | 1.81M | 11.19M | 22.58M | 16.93M | 22.35M | 6.17M | 4.32M | 1.78M | 204K |
| Short-Term Investments | 0 | 0 | 13.96M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.8M |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | 10.78K |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 1.61M | 422K | 507K | 0 | 1.19M | 0 | 1.21M | 1.06M | 795K | 1.2M |
| Total Non-Current Assets | 2.5M | 1.11M | 93.75M | 95.11M | 94.77M | 51.3M | 30.58M | 27.03M | 25.3M | 8.78M |
| Property, Plant & Equipment | 1.05M | 885K | 802K | 2.19M | 1.84M | 3.39M | 2.12M | 1.63M | 1.16M | 768K |
| Fixed Asset Turnover | 1.94x | 1.68x | 2.23x | 0.09x | - | - | - | - | - | 0.09x |
| Goodwill | 0 | 0 | 15.68M | 15.68M | 15.68M | 15.68M | 3.06M | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 77.09M | 77.09M | 77.09M | 32.07M | 25.25M | 25.25M | 24.13M | 8M |
| Long-Term Investments | 225K | 225K | 171K | 154K | 0 | 154K | 154K | 150K | 9K | 28K |
| Other Non-Current Assets | 1.23M | 0 | -195.98M | 154K | 154K | 154K | 154K | 0 | 0 | 10K |
| Total Assets | 9.7M▲ 0% | 3.35M▼ 65.5% | 119.4M▲ 3467.3% | 118.97M▼ 0.4% | 112.89M▼ 5.1% | 74.79M▼ 33.7% | 37.95M▼ 49.3% | 32.41M▼ 14.6% | 27.88M▼ 14.0% | 15.98M▲ 0% |
| Asset Turnover | 0.21x | 0.44x | 0.01x | 0.00x | - | - | - | - | - | 0.00x |
| Asset Growth % | -78.14% | -65.49% | 3467.31% | -0.35% | -5.12% | -33.75% | -49.25% | -14.62% | -13.98% | -61.71% |
| Total Current Liabilities | 13.39M | 11.76M | 20.63M | 7.82M | 6.13M | 4.92M | 2.46M | 4M | 5.72M | 21.9M |
| Accounts Payable | 1.81M | 3.05M | 3.42M | 1.71M | 1.16M | 693K | 249K | 809K | 1.88M | 1.65M |
| Days Payables Outstanding | 2.6K | 64.03 | 118.19 | 49.14K | 664.21 | 291.08 | 85.66 | 3.6K | 8.16K | 28.89K |
| Short-Term Debt | 0 | 0 | 7.97M | 161K | 352K | 294K | 252K | 233K | 661K | 3.13M |
| Deferred Revenue (Current) | 0 | 884K | 198K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 10.27M | 6.82M | 5.65M | 4.5M | 2.6M | 2.19M | 0 | 900K | 963K | 18.77M |
| Current Ratio | 0.54x | 0.19x | 1.24x | 3.05x | 2.96x | 4.77x | 3.00x | 1.35x | 0.45x | 0.45x |
| Quick Ratio | 0.54x | 0.19x | 1.24x | 3.05x | 2.96x | 4.77x | 3.00x | 1.35x | 0.45x | 0.45x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -18.11K |
| Total Non-Current Liabilities | 25.14M | 15.51M | 30.65M | 36.22M | 37.2M | 27.98M | 25.48M | 25.02M | 12.16M | 5.68M |
| Long-Term Debt | 25M | 15M | 15M | 4.61M | 2.42M | 15M | 0 | 15M | 0 | 240K |
| Capital Lease Obligations | 0 | 0 | 0 | 794K | 201K | 2.07M | 1.62M | 1.16M | 653K | 1.55M |
| Deferred Tax Liabilities | 0 | -15M | 15.48M | 15.82M | 16.78M | 7.11M | 5.06M | 5.06M | 4.53M | 15.89M |
| Other Non-Current Liabilities | 138K | 100K | 175K | 15M | 17.8M | 3.8M | 18.8M | 3.8M | 6.98M | 19.42M |
| Total Liabilities | 38.53M | 27.27M | 51.28M | 44.04M | 43.33M | 32.91M | 27.94M | 29.02M | 17.88M | 27.58M |
| Total Debt | 25M | 15M | 7.97M | 6.31M | 3.78M | 17.89M | 2.28M | 16.83M | 1.82M | 3.37M |
| Net Debt | 19.41M | 13.19M | -3.21M | -16.27M | -13.15M | -19.45M | -3.89M | 12.51M | 43K | 3.17M |
| Debt / Equity | - | - | 0.12x | 0.08x | 0.05x | 0.43x | 0.23x | 4.96x | 0.18x | 0.18x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.25x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.23x |
| Interest Coverage | -15.11x | -12.10x | -11.49x | -50.29x | -242.54x | -677.89x | -779.87x | -350.78x | -106.46x | 70.39x |
| Total Equity | -28.83M▲ 0% | -23.92M▲ 17.0% | 68.11M▲ 384.8% | 74.94M▲ 10.0% | 69.55M▼ 7.2% | 41.88M▼ 39.8% | 10.01M▼ 76.1% | 3.39M▼ 66.1% | 10M▲ 194.8% | 9K▲ 0% |
| Equity Growth % | -448.78% | 17.03% | 384.76% | 10.01% | -7.18% | -39.78% | -76.09% | -66.13% | 194.78% | 157.73% |
| Book Value per Share | -999999.00 | -999999.00 | 999999.00 | 308572.02 | 199938.67 | 76116.52 | 14302.86 | 787.51 | 190.10 | 0.34 |
| Total Shareholders' Equity | -28.83M | -23.92M | 68.11M | 74.94M | 69.55M | 41.88M | 10.01M | 3.39M | 10M | 9K |
| Common Stock | 9K | 3K | 32K | 41K | 17K | 28K | 0 | 0 | 0 | 36K |
| Retained Earnings | -618.67M | -637.11M | -657.65M | -685.12M | -717.69M | -785.32M | -824.53M | -844.82M | -846.61M | -889.37M |
| Treasury Stock | -3.05M | -3.05M | -3.05M | -3.05M | -3.05M | -3.05M | -3.05M | -3.05M | -3.05M | 0 |
| Accumulated OCI | -6.96M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
WINT Cash Flow Statement
Windtree Therapeutics, Inc. (WINT) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -33.59M | -21.05M | -15.78M | -24.66M | -25.32M | -23.66M | -19.45M | -13.44M | -15.4M | -15.4M |
| Operating CF Margin % | -1644.91% | -1417.17% | -882.61% | -12456.06% | - | - | - | - | - | - |
| Operating CF Growth % | -0.25% | 37.35% | 25.01% | -56.28% | -2.64% | 6.52% | 17.8% | 30.92% | -14.62% | 1.9% |
| Net Income | -39.49M | -18.45M | -20.53M | -27.48M | -32.57M | -67.64M | -39.21M | -20.29M | -1.79M | -40.86M |
| Depreciation & Amortization | 255K | 192K | 159K | 195K | 165K | 192K | 533K | 82K | 84K | 101K |
| Stock-Based Compensation | 1.69M | 1.66M | 955K | 6.72M | 5.68M | 7.24M | 3.09M | 1.28M | 455K | 142K |
| Deferred Taxes | -1.7M | 0 | 3.34M | 1.72M | 1.14M | -9.99M | -1.37M | 0 | -210K | -3.23M |
| Other Non-Cash Items | 3.17M | -4.91M | 863K | 882K | 1.59M | 46.59M | 19.28M | 3.48M | -15.31M | 27.05M |
| Working Capital Changes | 2.49M | 466K | -562K | -6.71M | -1.33M | -58K | -1.78M | 2.02M | 1.37M | 809K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.44M | 2.43M | 997K | -2.47M | -547K | -468K | -444K | 560K | 1.07M | -403K |
| Cash from Investing | -254K | -24K | -13.73M | 13.8M | -291K | -279K | 197K | -15K | -12K | -5.97M |
| Capital Expenditures | -281K | -24K | 0 | -191K | -291K | -279K | -13K | -15K | -12K | 0 |
| CapEx % of Revenue | 13.76% | 1.62% | - | 96.46% | - | - | - | - | - | - |
| Acquisitions | 27K | 0 | 223K | 0 | 0 | 0 | 210K | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 27K | 0 | 9K | 0 | 0 | 0 | 0 | 0 | 0 | -5.97M |
| Cash from Financing | 709K | 17.3M | 38.74M | 21.77M | 19.96M | 29.36M | 3.08M | 11.6M | 12.73M | 19M |
| Debt Issued (Net) | 0 | 3.9M | 6M | 0 | -3.23M | -3.87M | -1.17M | -797K | 1.26M | 1.91M |
| Equity Issued (Net) | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | -312K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -657K | -400K |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 483K |
| Other Financing | 709K | -2.5M | -155K | -1.21M | 2.94M | 5.84M | 0 | 843K | 8.52M | 17.77M |
| Net Change in Cash | -33.13M▲ 0% | -3.77M▲ 88.6% | 9.32M▲ 347.0% | 11.37M▲ 22.1% | -5.65M▼ 149.7% | 5.42M▲ 195.9% | -16.18M▼ 398.6% | -1.86M▲ 88.5% | -2.68M▼ 44.4% | -2.1M▲ 0% |
| Free Cash Flow | -33.87M▲ 0% | -21.07M▲ 37.8% | -15.78M▲ 25.1% | -24.85M▼ 57.5% | -25.61M▼ 3.0% | -23.94M▲ 6.5% | -19.46M▲ 18.7% | -13.45M▲ 30.9% | -15.41M▼ 14.6% | -15.12M▲ 0% |
| FCF Margin % | -1658.67% | -1418.79% | -882.61% | -12552.53% | - | - | - | - | - | -16801.11% |
| FCF Growth % | 0.27% | 37.79% | 25.1% | -57.49% | -3.03% | 6.49% | 18.7% | 30.89% | -14.59% | 1.14% |
| FCF per Share | -999999.00 | -999999.00 | -474167.62 | -102345.35 | -73608.66 | -43515.15 | -27807.14 | -3124.01 | -293.14 | -293.14 |
| FCF Conversion (FCF/Net Income) | 0.85x | 1.14x | 0.77x | 0.90x | 0.84x | 0.35x | 0.50x | 0.66x | 2.81x | 0.37x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
WINT Key Ratios
Windtree Therapeutics, Inc. (WINT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -92.92% | -38.41% | -41.91% | -121.39% | -151.11% | -302.78% | -81.98% | -453955.56% |
| Return on Invested Capital (ROIC) | - | - | -44.85% | -30.22% | -39.52% | -123.54% | -142.38% | -119.46% | -144.67% | -144.67% |
| Gross Margin | 87.51% | -1070.1% | -490.72% | 93.59% | - | - | - | - | - | 12.22% |
| Net Margin | -1933.89% | -1242.15% | -1148.38% | -13876.26% | - | - | - | - | - | -45395.56% |
| Debt / Equity | - | - | 0.12x | 0.08x | 0.05x | 0.43x | 0.23x | 4.96x | 0.18x | 0.18x |
| Interest Coverage | -15.11x | -12.10x | -11.49x | -50.29x | -242.54x | -677.89x | -779.87x | -350.78x | -106.46x | 70.39x |
| FCF Conversion | 0.85x | 1.14x | 0.77x | 0.90x | 0.84x | 0.35x | 0.50x | 0.66x | 2.81x | 0.37x |
| Revenue Growth | 106.89% | -27.28% | 20.4% | -88.93% | -100% | - | - | - | - | - |
WINT Frequently Asked Questions
Windtree Therapeutics, Inc. (WINT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Windtree Therapeutics, Inc. (WINT) reported $0.1M in revenue for fiscal year 2024. This represents a 10% decrease from $0.1M in 1995.
Windtree Therapeutics, Inc. (WINT) grew revenue by 0.0% over the past year. Growth has been modest.
Windtree Therapeutics, Inc. (WINT) reported a net loss of $40.9M for fiscal year 2024.
Dividend & Returns
Yes, Windtree Therapeutics, Inc. (WINT) pays a dividend with a yield of 100.00%. This makes it attractive for income-focused investors.
Windtree Therapeutics, Inc. (WINT) has a return on equity (ROE) of -82.0%. Negative ROE indicates the company is unprofitable.
Windtree Therapeutics, Inc. (WINT) had negative free cash flow of $15.1M in fiscal year 2024, likely due to heavy capital investments.
Explore More WINT
Windtree Therapeutics, Inc. (WINT) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates